The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Somov A.N.

Samarskiĭ oblastnoĭ klinicheskiĭ onkologicheskiĭ dispanser

Suslin S.A.

Samara State Medical University, Ministry of Health of Russia, Samara, Russia

Prostate cancer. Epidemiology, risk factors and early detection

Authors:

Somov A.N., Suslin S.A.

More about the authors

Journal: Russian Journal of Preventive Medicine. 2020;23(3): 149‑155

DOI: 10.17116/profmed202023031149

Read: 7241 times

Download PDF (RU)
Contact the author
Table of contents

PROSTATE CANCER. EPIDEMIOLOGY, RISK FACTORS AND EARLY DETECTION
PROSTATE CANCER. EPIDEMIOLOGY, RISK FACTORS AND EARLY DETECTION

To cite this article:

Somov AN, Suslin SA. Prostate cancer. Epidemiology, risk factors and early detection. Russian Journal of Preventive Medicine. 2020;23(3):149‑155. (In Russ.)
https://doi.org/10.17116/profmed202023031149

 
Подписка 2026 Профилактическая медицина (Russian Journal of Preventive Medicine)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Prostate cancer worldwide occupies a leading position in the structure of cancer and mortality from malignant neoplasms among men. Significant economic costs associated with the treatment of this pathology, as well as the disability of male population, indicate the need to develop measures aimed at the prevention and early detection of prostate cancer. There are a large number of randomized trials describing models for early detection of prostate cancer, but there is no consensus on the appropriateness of screening for this pathology. An analysis of articles on risk factors, early detection and epidemiological features of prostate cancer distribution by foreign and domestic authors for the period from 1992 to 2017 was carried out.

Keywords:

prostate cancer
epidemiology
early detection
risk factors

Authors:

Somov A.N.

Samarskiĭ oblastnoĭ klinicheskiĭ onkologicheskiĭ dispanser

Suslin S.A.

Samara State Medical University, Ministry of Health of Russia, Samara, Russia

Close metadata

References:

  1. Ahmedin J, Freddie B, Melissa MC. Global Cancer Statistics. CA: Cancer J CLIN. 2011;61:69-90. https://doi.org/10.3322/caac.v61:2
  2. Vazhenin AV, Karnauh PA. Tendencii epidemiologii raka predtate’noj zhelezy v Chelyabinskoj oblasti. Onkourologiya. 2008;3:67-68. (In Russ.).
  3. Andriole G, Craftford E, Grubb R. Mortality results from a randomized prostate-cancer screening trial. New England Journal of Medicine. 2009;360(13): 1310-1319. https://doi.org/10.1056/nejmoa0810696
  4. Boyle P, Maisonneuve P, Napalkov P. Incidence of Prostate Cancer will double by the Year 2030: The Argument For. European Urology. 1996;29:3-9. https://doi.org/10.1159/000473828
  5. Kitaev SV. Diagnostika raka predstatel’noj zhelezy: sovremennoe sostoyanie voprosa. Chast’ 1. Skriningovye metody issledovaniya. Medicinskaya vizualizaciya. 2008;4:121-126. (In Russ.).
  6. Hsing A. International trends and patterns of prostate cancer incidence and mortality. International Journal Cancer. 2000;85(1):60-67. https://doi.org/10.1002/(sici)1097-0215(20000101)85:1<60::aid-ijc11>3.3.co;2-2
  7. Quinn M. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU International. 2002;90(2):162-173. https://doi.org/10.1046/j.1464-410x.2002.2822.x
  8. Iremashvili VV. Metabolicheskij sindrom i rak predstatel’noj zhelezy: est’ li svyaz’? RMZh. 2009;25:1667-1671. (In Russ.).
  9. Davydov MI, Aksel’ EM. Statistika zlokachestvennyh novoobrazovanij v Rossii i stranah SNG v 2008 g. Vestnik RONC im. NN Blohina RAMN. 2010; 21(2-1):160.
  10. Chissova VI, Starinskij VV, Petrova GV. Zlokachestvennye novoobrazovaniya v Rossii v 2010 g. (zabolevaemost’ i smertnost’). M.: FGU «MNIOI im. PA Gercena Rosmedtehnologij»; 2011. (In Russ.).
  11. Kaprin AD, Starinskij VV. Zlokachestvennye novoobrazovaniya v Rossii (obzor statisticheskoj informacii za 1993—2013 gg.). M.: MNIOI im. PA Gercena — filial FGBU «NMIRC» Minzdrava Rossii; 2015. (In Russ.).
  12. Propashhev YuYu, Oshhepkov VN. Voprosy diagnostiki raka predstatel’noj zhelezy. Nauchnyj forum. Sibir’. 2017;3(2):40-41. (In Russ.).
  13. Matveev BP. Statistika onkourologicheskih zabolevanij. Aktual’nye voprosy lecheniya onkourologicheskih zabolevanij. Materialy V Vserossijskoj nauchno-prakticheskoj konferencii onkourologov. Obninsk. 2003.
  14. Fedorov NM, Lykov AV, Podgal’naya EB. Epidemologiya raka predstatel’noj zhelezy v Tyumenskoj oblasti. Akademicheskij zhurnal zapadnoj Sibiri. 2017; 3(70):10-12. (In Russ.).
  15. Derevyanko TI, Panchenko IA, Marabyan ES, Garmash ON. Ambulatornaya diagnostika mestnolokalizovannogo raka predstatel’noj zhelezy. Nauchno-medicinskij vestnik central’nogo Chernozem’ya. 2014;55:47-51. (In Russ.).
  16. Gevorkyan AR. Faktory riska, sovremennye osobennosti zabolevaemosti i smertnosti ot raka predstatel’noj zhelezy v Moskve. Vestnik Ivanovskoj medicinskoj akademii. 2017;22(1):40-46. (In Russ.).
  17. Volgareva GM. Rak predstatel’noj zhelezy: vozmozhnaya rol’ papillomavirusov v ego vosniknovenii. Vestnik Rossijskoj akademii medicinskih nauk. 2015;70(1):95-100. (In Russ.). https://doi.org/10.15690/vramn.v70i1.1237
  18. Kostin AA, Asratov AT, Kul’chenko NG. Prognozirovanie razvitiya raka predstatel’noj zhelezy s pomoshh’yu obshhih modelej diskriminantnogo analiza. Vestnik Rossijskogo universiteta druzhby narodov. Seriya: Medicina. 2015; 3:67-74. (In Russ.).
  19. Pavlova TV, Kulikovskij VF, Pavlova LA. Klinicheskaya i eksperimental’naya morfologiya. M.: Medicinskoe informacionnoe agenstvo; 2016. (In Russ.).
  20. Ganov DI, Fedoskina AV, Varlamov SA, Aver’yanova MV, Lazarev AF. Epidemiologiya raka predstatel’noj zhelezy v Altajskom krae. Rossijskij onkologicheskij zhyrnal. 2014;19(6):40-43. (In Russ.).
  21. Ankerst DP, Boeck A, Freedland SJ, Jones JS, Cronin AM, Roobol MJ, Hugosson J, Kattan MW, Klein EA, Hamdy F, Neal D, Donovan J, Parekh DJ, Klocker H, Horninger W, Benchikh A, Salama G, Villers A, Moreira DM, Schröder FH, Lilja H, Vickers AJ, Thompson IM. Evaluating the Prostate Cancer Prevention Trial High Grade prostate cancer risk calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World Journal of Urology. 2014;32(1):185-191. https://doi.org/10.1007/s00345-012-0869-2
  22. Braun S, Bitton-Worms K, LeRoith D. The link between the metabolic syndrome and cancer. International Journal of Biological Sciences. 2011;7(7):1003-1015. https://doi.org/10.7150/ijbs.7.1003
  23. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. European Journal of Cancer. 2013;49(6):1374-1403. https://doi.org/10.1016/j.ejca.2012.12.027
  24. Chissov VI, Rusakov IG. Zabolevaemost’ rakom predstatel’noj zhelezy v Rossijskoj Federacii. Eksperimental’naya i klinicheskaya urologiya. 2011;2-3:6-7. (In Russ.).
  25. Kul’chenko NG, Tolkachev AO. Rak predstatel’noj zhelezy v 21 veke. Obzor literatury. Vestnik medicinskogo instituta «Reaviz». 2017;6(30):106-113. (In Russ.).
  26. Barchuk AA. Perspektivy populyacionnogo skrininga raka predstatel’noj zhelezy. Demograficheskoe obozrenie. 2017;4(3):181-189. (In Russ.). https://doi.org/10.17323/demreview.v4i3.7322
  27. Rozner VEA, Hrakovskij SI, Zelenyj AI. Faktory riska razvitiya raka predstatel’noj zhelezy u rabotnikov promyshlennyh predpriyatij s vrednymi I opasnymi usloviyami truda v g. Komsomol’sk-na-amure. Optimizaciya rannej diagnostiki (na primere rabotnikov KNAAPO, ASZ, KNPZ, AMURMETALL). Ekologiya i bezopasnost’ zhiznedeyatel’nosti. 2010;1:85-92. (In Russ.).
  28. Alekseevna GN, Gurina GI. Celevaya dispanserizaciya muzhchin s zabolevaniyami predstatel’noj zhelezy. Tihookeanskij medicinskij zhurnal. 2005; 4(22):77-79. (In Russ.).
  29. Pavlov IA, Pavlova TV, Buhvalov IB, Pil’kevich NB, Bessmertnyj DV, Chaplygina MA, Goncharov IYu, Kolesnikov DA. Patogeneticheskie aspekty raka predstatel’noj zhelezy. Ural’skij medicinskij zhurnal. 2017;4(148):66-69. (In Russ.).
  30. Aksel’ EM. Zabolevaemost’ zlokachestvennymi novoobrazovaniyami mochevyh i muzhskih polovyh organov v Rossii v 2003 g. Onkourologiya. 2005; 1:6-9. (In Russ.).
  31. Chissov VV, Starinskij VV, Aleksandrova LM, Lutkovskij AS, Savinov VA, Petrova GV, Grecova OP, Boriseeva NV, Bylkova ES, Harchenko NV. O sovershenstvovanii onkologicheskoj sluzhby i uluchshenii onkologicheskoj pomoshhi naseleniyu Rossijskoj Federacii. Prakticheskaya medicina. 2009; 4(36):97-101. (In Russ.).
  32. Gevorkyan AP, Bersneva EA. Opyt organizacii raboty ambulatornoj urologicheskoj sluzhby po rannemu vyyavleniyu raka predstatel’noj zhelezy. Sovremennaya medicina: aktual’nye voprosy I perspektivy razvitiya. Sbornik nauchnyh trudov po itogam mezhdunarodnoj nauchno-prakticheskoj konferencii. M.: Innovacionnyj centr razvitiya obrazovaniya i nauki; 2017. (In Russ.).
  33. Vorob’ev AV, Krzhivickij PI. Perspektivy, profilaktika, diagnostika i stadirovanie raka predstatel’noj zhelezy. Prakticheskaya onkologiya. 2008;9(2):71-82. (In Russ.).
  34. Passevich KG, Cherenkov VG, Petrov AB, Strozhenkov MM. Mnogoetapnyj skrinning raka predstatel’noj zhelezy. Vestnik Novogorodskogo gosudarstvennogo universiteta. 2012;66:67-70. (In Russ.).
  35. Beyersdorff D, Taupitz M, Winkelmann B. Patients with a history of elevated prostate specific antigen levels and negative transrectal US-guided quadrant of sextant biopsy results: value of MR imaging. Radiology. 2002;224(3): 701-706. https://doi.org/10.1148/radiol.2243011553
  36. Chigireva IB, Hasanov RSh, Gilyazutdinov IA, Panchenko SV, Shakirov KT. Rannyaya diagnostika raka predstatel’noj zhelezy. Prakticheskaya medicina. 2013;2(67):108-11. (In Russ.).
  37. De Koning HJ, Liem MK, Baan CA, Boer R, Schröder FH, Alexander FE; ERSPC. Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomised for Prostate Cancer (ERSPC) trial. International Journal Cancer. 2002;98(2):268-273. https://doi.org/10.1002/ijc.10188
  38. Schroder FN, Roobol MJ. European Randomized Study of screening for Prostate Cancer (ERSPC): rationale, structure and preliminary results 1994—2003. BJU International. 2003;92(2).
  39. Krasnyj SA, Tarend’ DT, Sukonko OG, Moiseev PI. Pervyj opyt skrininga raka predstatel’noj zhelezy v respublike Belarus’. Sibirskij onkologicheskij zhurnal. 2013;3:66-69. (In Russ.).
  40. Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL, Lange PH. Screening for Prostatic Carcinoma with Prostate Specific Antigen. The journal of urology. 1992;147(2):841-845. https://doi.org/10.1016/s0022-5347(17)37401-3
  41. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994;271(5):368-374.
  42. Davydov MI, Zaridze DG. Skrinning zlokachestvennyh opuholej: sovremennoe sostoyanie i perspektivy. Vestnik Moskovskogo onkologicheskogo obshhestva. 2014;3(606):2-6. (In Russ.).
  43. Catalona WJ, Richie JP, Ahmann FR. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. The journal of urology. 1994;5(151):1283-1290. https://doi.org/10.1016/s0022-5347(17)35233-3
  44. Glenski WJ, Malek RS, Myrtler JF. Sustained, Substantially Increased Concentration of Prostate-Specific Antigen in the Absence of Prostatic Malignant Disease: An Unusual Clinical Scenario. Mayo Clin Proc. 1992;67(3):249-252. https://doi.org/10.1016/s0025-6196(12)60101-3
  45. Matveev BP, Buharkin BV, Matveev VB. Rak predstatel’noj zhelezy. M.; 1999. (In Russ.).
  46. Oesterling JE, Jacobsen SJ, Chutte CG. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA. 1993;7(270):860864. https://doi.org/10.1001/jama.1993.03510070082041
  47. Crawford ED. Epidemiology of prostate cancer. Urology. 2003;62(6):3-12. https://doi.org/10.1016/j.urology.2003.10.013
  48. Harchenko VP, Kaprin AD, Pan’shin GA, Milenin KP, Al’bickij IA, Cybul’skij AD. Brahiterapiya — sovremennyj metod radikal’nogo lecheniya lokalizovannogo raka predstatel’noj zhelezy. Radiologiya — praktika. 2008;6:35-39. (In Russ.).
  49. Vorob’ev AV. Skrining muzhskogo naseleniya, standartnoe obsledovanie pacientov, klassifikaciya raka predstatel’noj zhelezy. Prakticheskaya onkologiya. 2001;2(2):8-16. (In Russ.).
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.